The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
If your back has been bothering you, consider your recent activities before chalking up your pain to RA
Current Insight of Peptide-Based Hydrogels for Chronic Wound Healing Applications: A Concise Review
The majority of participants reported mild to moderate side effects that were not long-term
Programmatic deprescribing across a broad population may seem like an easy answer
High levels are often a marker, not a causeusually due to supplements or underlying conditions
